These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 8029479)

  • 1. Inhibition of the pharmacological effects of endothelin.
    Wilson C; Hargreaves RB
    Prog Med Chem; 1994; 31():371-410. PubMed ID: 8029479
    [No Abstract]   [Full Text] [Related]  

  • 2. Endothelins are potent vasoconstrictors, and much more besides.
    Gray GA; Battistini B; Webb DJ
    Trends Pharmacol Sci; 2000 Feb; 21(2):38-40. PubMed ID: 10733432
    [No Abstract]   [Full Text] [Related]  

  • 3. [Prospects for endothelin-related drugs].
    Goto K
    Nihon Rinsho; 2004 Sep; 62 Suppl 9():673-81. PubMed ID: 15506472
    [No Abstract]   [Full Text] [Related]  

  • 4. Recent developments in endothelin research.
    Bennett T; Gardiner SM
    J Hum Hypertens; 1994 Aug; 8(8):587-92. PubMed ID: 7990086
    [No Abstract]   [Full Text] [Related]  

  • 5. Endothelin receptor antagonists: actions and rationale for their development.
    Warner TD; Battistini B; Doherty AM; Corder R
    Biochem Pharmacol; 1994 Aug; 48(4):625-35. PubMed ID: 8080434
    [No Abstract]   [Full Text] [Related]  

  • 6. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs.
    Lüscher TF; Barton M
    Circulation; 2000 Nov; 102(19):2434-40. PubMed ID: 11067800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelin blockers and renal protection: a new strategy to prevent end-organ damage in cardiovascular disease?
    Rabelink TJ; Stroes ES; Bouter KP; Morrison P
    Cardiovasc Res; 1998 Sep; 39(3):543-9. PubMed ID: 9861295
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of endothelin-converting enzyme inhibitors on big endothelin-1 induced contraction of rabbit basilar artery.
    Zimmermann M; Jung C; Raabe A; Spanehl O; Seifert V
    Acta Neurochir Suppl; 2001; 77():73-5. PubMed ID: 11563313
    [No Abstract]   [Full Text] [Related]  

  • 9. [Involvement of endothelin in the pathogenesis of hypertension and hypertensive target-organ damage].
    Kanno K; Hirata Y
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():164-8. PubMed ID: 15171363
    [No Abstract]   [Full Text] [Related]  

  • 10. Utility of endothelin-converting enzyme inhibitors for the treatment of cardiovascular diseases.
    Jeng AY
    Curr Opin Investig Drugs; 2003 Sep; 4(9):1076-81. PubMed ID: 14582451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there a role for endothelin antagonists in diabetic renal disease?
    Jandeleit-Dahm K; Allen TJ; Youssef S; Gilbert RE; Cooper ME
    Diabetes Obes Metab; 2000 Jan; 2(1):15-24. PubMed ID: 11220349
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of phosphoramidon (endothelin converting enzyme inhibitor) and BQ-123 (endothelin receptor subtype A antagonist) on blood pressure in hypertensive rats.
    McMahon EG; Palomo MA; Brown MA; Bertenshaw SR; Carter JS
    Am J Hypertens; 1993 Aug; 6(8):667-73. PubMed ID: 8217029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology.
    Rubanyi GM; Polokoff MA
    Pharmacol Rev; 1994 Sep; 46(3):325-415. PubMed ID: 7831383
    [No Abstract]   [Full Text] [Related]  

  • 14. Rhamnose moiety of phosphoramidon is not required for in vivo inhibition of endothelin converting enzyme.
    Pollock DM; Shiosaki K; Sullivan GM; Opgenorth TJ
    Biochem Biophys Res Commun; 1992 Jul; 186(2):1146-50. PubMed ID: 1497648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. California dreamin' 'bout endothelin: emerging new therapeutics.
    Warner TD; Elliott JD; Ohlstein EH
    Trends Pharmacol Sci; 1996 May; 17(5):177-81. PubMed ID: 8669122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The role of endothelin in the realization of the length-strength ratio of vascular smooth muscles in rats].
    Tkachenko MN; Sagach VF
    Fiziol Zh Im I M Sechenova; 1995 Sep; 81(9):60-4. PubMed ID: 8581054
    [No Abstract]   [Full Text] [Related]  

  • 17. The therapeutic potential of endothelin-1 receptor antagonists and endothelin-converting enzyme inhibitors on the cardiovascular system.
    Doggrell SA
    Expert Opin Investig Drugs; 2002 Nov; 11(11):1537-52. PubMed ID: 12437501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Endothelin and kidney disease].
    Nakayama Y; Tomita K
    Nihon Rinsho; 2004 Sep; 62 Suppl 9():655-60. PubMed ID: 15506468
    [No Abstract]   [Full Text] [Related]  

  • 19. The discovery of endothelins.
    Masaki T
    Cardiovasc Res; 1998 Sep; 39(3):530-3. PubMed ID: 9861293
    [No Abstract]   [Full Text] [Related]  

  • 20. Big endothelin analogues with inhibitory activity on endothelin-converting enzyme-1.
    Takayanagi R; Liu W; Ito T; Ohnaka K; Nawata H
    J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S62-3. PubMed ID: 9595401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.